# A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

> **NCT01981499** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 31 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** PF-05180999
- **DRUG:** Placebo
- **DRUG:** 120 mg MR PF-05180999
- **DRUG:** 360 mg MR PF-05180999
- **DRUG:** 10 mg cetirizine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01981499
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** The trial was prematurely terminated on 01April2014 due to safety concerns.
- **Last updated:** 2014-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01981499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01981499, "A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01981499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*